Loading
A phase 1/2 trial of ABSK141-400mg in advanced solid tumours, run by Abbisko Therapeutics Co, Ltd, now recruiting.
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) is a phase 1/2 interventional study registered as NCT07417189 by Abbisko Therapeutics Co, Ltd, with 401 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-12-30. Interventions recorded: ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg, ABSK141-1200mg and ABSK141-Recommended Phase 2 dose (RP2D).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/